[Age-related transformation of infantile spasms into drug-resistant forms of epilepsy]

Insights

Infantile spasms (IS) treatment outcomes varied significantly. Group 2 patients achieved longer remission and better EEG results with hormone therapy and antiepileptic drugs (AEDs), unlike drug-resistant Group 1.

Area of Science:

  • Pediatrics
  • Neurology
  • Epileptology

Context:

  • Infantile spasms (IS) present a significant challenge in pediatric neurology.
  • Understanding treatment resistance and long-term outcomes is crucial for managing IS.
  • Hypsarrhythmia and evolving seizure patterns complicate therapeutic strategies.

Purpose:

  • To investigate treatment outcomes for infantile spasms (IS) considering evolutionary aspects and drug resistance.
  • To compare remission periods and EEG changes in IS patients receiving standard hormone therapy and antiepileptic drugs (AEDs).
  • To analyze the impact of adding multiple AEDs on refractory IS cases.

Summary:

  • This study followed 73 children with IS, dividing them into two groups based on remission duration after initial hormone and valproate treatment.
  • Group 1 (n=12) showed short remission (0-4 months) and persistent hypsarrhythmia, with high recurrence rates (83%) and limited response to additional AEDs.
  • Group 2 (n=9) experienced longer remission (7 months-4 years), cessation of IS in all cases, and improved EEG findings, with some developing focal seizures responsive to further AEDs.

Impact:

  • The findings highlight distinct therapeutic responses in IS, differentiating between drug-resistant and remitting cases.
  • Longer remission and improved EEG activity in Group 2 suggest a more favorable prognosis with initial hormone therapy.
  • The study underscores the age-dependent nature of IS evolution and the limited efficacy of adding multiple AEDs in drug-resistant forms.

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...